What is Ostia Sciences?
Ostia Sciences Inc. is a pioneering biotech startup dedicated to developing beneficial microbes for combating infectious diseases and bolstering immune function. The company has distinguished itself with innovations such as Salivaricin 10, recognized as the world's first phosphorylated antibiotic. Ostia Sciences champions a microbiome-centric approach to healthcare, leveraging a cutting-edge research platform to identify and characterize probiotics with potent drug-like characteristics. Their work holds significant promise for disease prevention and therapeutic interventions within the healthcare sector.
How much funding has Ostia Sciences raised?
Ostia Sciences has raised a total of $1M across 1 funding round:
Seed
$1M
Seed (2025): $1M, investors not publicly disclosed
What's next for Ostia Sciences?
The recent major enterprise-level funding positions Ostia Sciences for significant expansion and further research and development. This capital infusion is expected to accelerate the commercialization of their unique microbiome-based therapies and solidify their market presence. The company's focus on novel antibiotic development and immune enhancement through probiotics indicates a strategic move towards addressing critical unmet needs in infectious disease management and broader healthcare innovation.
See full Ostia Sciences company page
